Screener
Vir Biotechnology, Inc. VIR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Vir Biotechnology, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
FAQ
- What is Vir Biotechnology, Inc.'s return on equity?
- Vir Biotechnology, Inc. (VIR) reported return on equity of -26.1% in Q2 2026.
- How has Vir Biotechnology, Inc.'s return on equity changed year-over-year?
- Vir Biotechnology, Inc.'s return on equity increased by 43.6% year-over-year, from -46.2% to -26.1%.
- What is the long-term trend for Vir Biotechnology, Inc.'s return on equity?
- Over 4 years (2020 to 2025), Vir Biotechnology, Inc.'s return on equity has grown at a -3.3% compound annual growth rate (CAGR), from -52.4% to -45.7%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Vir Biotechnology, Inc.'s return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude